Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Introduction: Abemaciclib is an oral, selective small-molecule CDK 4 and 6 inhibitor. In preclinical models, abemaciclib synergized with programmed cell death protein-1 blockade to enhance antitumor efficacy. Here, we report the safety and anticancer activity of abemaciclib plus pembrolizumab in two...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jean-Louis Pujol, MD, PhD, Johan Vansteenkiste, MD, PhD, Luis Paz-Ares Rodríguez, MD, PhD, Vanesa Gregorc, MD, Julien Mazieres, MD, PhD, Mark Awad, MD, PhD, Pasi A. Jänne, MD, PhD, Michael Chisamore, PhD, Anwar M. Hossain, MStat, Yanyun Chen, PhD, J. Thaddeus Beck, MD, FACP
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Abemaciclib
KRAS-mutant
PD-L1 positive non–small cell lung cancer
Pembrolizumab
Squamous
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/c9caff189596499fa7e9767a030f2c97
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c9caff189596499fa7e9767a030f2c97

Ejemplares similares